Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis

Journal of Hepatology

Volumn 47, Issue 4, 2007, Pages 565-570

  Balas, Bogdan ^a   Belfort, Renata ^a   Harrison, Stephen A ^a   Darland, Celia ^b   Finch, Joan ^b   Schenker, Steven ^c   Gastaldelli, Amalia ^a,d   Cusi, Kenneth ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^c BROOKE ARMY MEDICAL CENTER   (United States)

^d INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

Non alcoholic steatohepatitis (NASH); Pioglitazone; Total body fat; Total body water

Indexed keywords

PIOGLITAZONE; PLACEBO;

ADULT; ARTICLE; BODY FAT; BODY MASS; BODY WATER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFECT; EDEMA; EXTRACELLULAR FLUID; FEMALE; HUMAN; HYDRATION; INSULIN RESISTANCE; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WEIGHT GAIN;

ADIPOSE TISSUE; BLOOD GLUCOSE; BODY WATER; FATTY LIVER; FEMALE; HEPATITIS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; THIAZOLIDINEDIONES; WEIGHT GAIN;

EID: 34548200442     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2007.04.013     Document Type: Article

References (50)

1. Marchesini G., Bugianesi E., Forlani G., Cerrelli F., Lenzi M., Manini R., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37 (2003) 917-923
2. Browning J.D., Szczepaniak L.S., Dobbins R., Nuremberg P., Horton J.D., Cohen J.C., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40 (2004) 1387-1395
3. Fassio E., Alvarez E., Dominguez N., Landeira G., and Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 40 (2004) 820-826
4. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Zoli M., and Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 358 (2001) 893-894
5. Promrat K., Lutchman G., Uwaifo G.I., Freedman R.J., Soza A., Heller T., et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39 (2004) 188-196
6. Neuschwander-Tetri B.A., Brunt E.M., Wehmeier K.R., Oliver D., and Bacon B.R. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38 (2003) 1008-1017
7. Belfort R., Harrison S.A., Brown K., Darland C., Finch J., Hardies J., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355 (2006) 2297-2307
8. Boden G., and Zhang M. Recent findings concerning thiazolidinediones in the treatment of diabetes. Expert Opin Investig Drugs 15 (2006) 243-250
9. Kelly I.E., Han T.S., Walsh K., and Lean M.E. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 22 (1999) 288-293
10. Mori Y., Murakawa Y., Okada K., Horikoshi H., Yokoyama J., Tajima N., et al. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 22 (1999) 908-912
11. Pavo I., Jermendy G., Varkonyi T.T., Kerenyi Z., Gyimesi A., Shoustov S., et al. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab 88 (2003) 1637-1645
12. Hanefeld M., Brunetti P., Schernthaner G.H., Matthews D.R., Charbonnel B.H., and QUARTET Study Group. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 27 (2004) 141-147
13. Charbonnel B., Roden M., Urquhart R., Mariz S., Johns D., Mihm M., et al. Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens. Diabetologia 48 (2005) 553-560
14. Tan M., Johns D., Gonzalez Galvez G., Antunez O., Fabian G., Flores-Lozano F., et al. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in mexican patients with type 2 diabetes mellitus: a multicenter, randomized, double-blind, parallel-group trial. Clin Ther 26 (2004) 680-693
15. Kahn S.E., Haffner S.M., Heise M.A., Herman W.H., Holman R.R., Jones N.P., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355 (2006) 2427-2443
16. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macroVascular events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
17. Azen S.P., Peters R.K., Berkowitz K., Kjos S., Xiang A., and Buchanan T.A. TRIPOD (TRoglitazone in the prevention of diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin Trials 19 (1998) 217-231
18. Actos prescribing information. Lincolnshire, IL: Takeda Pharmaceuticals America, Inc., Revised: February 2007.
19. Nesto R.W., Bell D., Bonow R.O., Fonseca V., Grundy S.M., Horton E.S., et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 27 (2004) 256-263
20. Karter A.J., Ahmed A.T., Liu J., Moffet H.H., and Parker M.M. Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet Med 22 (2005) 986-993
21. Berria R, Glass L, Mahankali A, Miyazaki Y, Monroy A, DeFilippis E, et al. Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in type 2 diabetes mellitus. Clin Pharmacol Ther, advance online publication 14 March 2007; doi: 10.1038/sj.c1pt.6100146.
22. Berria R., Gastaldelli A., Lucidi S., Belfort R., De Filippis E., Easton C., et al. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome. Clin Pharmacol Ther 80 (2006) 105-114
23. Kinley J., and Urquhart R. Effect of pioglitazone on water volumes in patients with type 2 diabetes. Diabetologia 48 (2005) A281
24. Basu A., Jensen M.D., McCann F., Mukhopadhyay D., Joyner M.J., and Rizza R.A. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care 29 (2006) 510-514
25. Lukaski H.C., Marchello M.J., Hall C.B., Schafer D.M., and Siders W.A. Soft tissue composition of pigs measured with dual X-ray absorptiometry: comparison with chemical analyses and effects of carcass thicknesses. Nutrition 15 (1999) 697-703
26. Hume R., and Weyers E. Relationship between total body water and surface area in normal and obese subjects. J Clin Pathol 24 (1971) 234-238
27. Brozek J., Grande F., Anderson J.T., and Keys A. Densitometric analysis of body composition: revision of some quantitative assumptions. Ann N Y Acad Sci 110 (1963) 113-140
28. Chumlea W.C., and Guo S.S. Bioelectrical impedance and body composition: present status and future directions. Nutr Rev 52 (1994) 123-131
29. van Marken Lichtenbelt W.D., Westerterp K.R., Wouters L., and Luijendijk S.C. Validation of bioelectrical-impedance measurements as a method to estimate body-water compartments. Am J Clin Nutr 60 (1994) 159-166
30. Ellis K.J., and Wong W.W. Human hydrometry: comparison of multifrequency bioelectrical impedance with 2H2O and bromine dilution. J Appl Physiol 85 (1998) 1056-1062
31. Harrison S.A. New treatments for nonalcoholic fatty liver disease. Curr Gastroenterol Rep 8 (2006) 21-29
32. Scheltinga M.R., Jacobs D.O., Kimbrough T.D., and Wilmore D.W. Alterations in body fluid content can be detected by bioelectrical impedance analysis. J Surg Res 50 (1991) 461-468
33. Miyazaki Y., Mahankali A., Matsuda M., Mahankali S., Hardies J., Cusi K., et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 87 (2002) 2784-2791
34. Smith S.R., De Jonge L., Volaufova J., Li Y., Xie H., and Bray G.A. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism 54 (2005) 24-32
35. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 351 (2004) 1106-1118
36. Xiang A.H., Peters R.K., Kjos S.L., Marroquin A., Goico J., Ochoa C., et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in hispanic women with prior gestational diabetes. Diabetes 55 (2006) 517-522
37. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Gerstein H.C., Yusuf S., Bosch J., Pogue J., Sheridan P., Dinccag N., et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368 (2006) 1096-1105
38. Blanc S., Colligan A.S., Trabulsi J., Harris T., Everhart J.E., Bauer D., et al. Influence of delayed isotopic equilibration in urine on the accuracy of the (2)H(2)(18)O method in the elderly. J Appl Physiol 92 (2002) 1036-1044
39. Schoeller D.A., and van Santen E. Measurement of energy expenditure in humans by doubly labeled water method. J Appl Physiol 53 (1982) 955-959
40. Jankowski C.M., Sonko B.J., Gozansky W.S., and Kohrt W.M. Deuterium dilution: the time course of 2H enrichment in saliva, urine, and serum. Clin Chem 50 (2004) 1699-1701
41. van Marken Lichtenbelt W.D., Westerterp K.R., and Wouters L. Deuterium dilution as a method for determining total body water: effect of test protocol and sampling time. Br J Nutr 72 (1994) 491-497
42. Schloerb P.R., Friis-Hansen B.J., Edelman I.S., Solomon A.K., and Moore F.D. The measurement of total body water in the human subject by deuterium oxide dilution; with a consideration of the dynamics of deuterium distribution. J Clin Invest 29 (1950) 1296-1310
43. Wang Z., Deurenberg P., Wang W., Pietrobelli A., Baumgartner R.N., and Heymsfield S.B. Hydration of fat-free body mass: review and critique of a classic body-composition constant. Am J Clin Nutr 69 (1999) 833-841
44. Sheng H.P., and Huggins R.A. A review of body composition studies with emphasis on total body water and fat. Am J Clin Nutr 32 (1979) 630-647
45. Kubota N., Terauchi Y., Miki H., Tamemoto H., Yamauchi T., Komeda K., et al. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 4 (1999) 597-609
46. Okuno A., Tamemoto H., Tobe K., Ueki K., Mori Y., Iwamoto K., et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese zucker rats. J Clin Invest 101 (1998) 1354-1361
47. Bogacka I., Xie H., Bray G.A., and Smith S.R. The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo. Diabetes Care 27 (2004) 1660-1667
48. Brown J.D., and Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation 115 (2007) 518-533
49. Glorian M., Duplus E., Beale E.G., Scott D.K., Granner D.K., and Forest C. A single element in the phosphoenolpyruvate carboxykinase gene mediates thiazolidinedione action specifically in adipocytes. Biochimie 83 (2001) 933-943
50. Tordjman J., Chauvet G., Quette J., Beale E.G., Forest C., and Antoine B. Thiazolidinediones block fatty acid release by inducing glyceroneogenesis in fat cells. J Biol Chem 278 (2003) 18785-18790